Letter | Published:

Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis

Naturevolume 287pages334335 (1980) | Download Citation



Infectious mononucleosis (IM) is usually a benign lymphoproliferative disease caused by Epstein–Barr virus (EBV)1. Although EBV induces a state of continuous proliferation in infected B lymphocytes in vitro2,3, the most prominent lymphoproliferation during IM is of activated, or atypical, T lymphocytes presumably responding to the virus or virus-infected cells4. However, EBV genome-carrying cells are known to be circulating during IM, as cultured peripheral blood leukocytes from patients with the disease give rise to continuous lymphoblastoid cell lines, each cell of which contains the EBV genome and expresses the EBV determined nuclear antigen (EBNA)5,6. The proposal that EBV-infected cells in IM blood are not endowed with enhanced growth potential but are merely latently infected7 is supported by demonstrations that cells infected in vivo enter a viral replicative cycle when placed in vitro and that most cell lines derived from cultured lymphocytes of IM patients are infected by virus released in vitro8. However the cells could also be capable of proliferation in vivo, since virus production and transformation are not mutually exclusive properties of EBV-transformed cells9. Recently, EBNA has been detected in a very small fraction of peripheral blood lymphocytes of IM patients after T cells were first removed10,11 and this has been interpreted to indicate that cell transformation occurs in vivo during IM. The isolation of colonies of EBNA-positive cells from IM blood leukocytes cultures in soft agar suggests that at least some infected cells are capable of direct outgrowth into transformed cells12. We report here direct evidence that circulating EBV-infected cells exhibit increased growth properties during IM.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Henle, G., Henle, W. & Diehl, V. Proc. natn. Acad. Sci. U.S.A. 59, 94–101 (1968).

  2. 2

    Jondal, M. & Klein, G. J. exp. Med. 138, 1365–1378 (1973).

  3. 3

    Robinson, J., Andiman, W., Henderson, E. & Miller, G. Proc. natn. Acad. Sci. U.S.A. 74, 749–753 (1977).

  4. 4

    Sheldon, P., Papamichael, M., Hemsted, E. & Holborow, E. Lancet i, 1153–1157 (1973).

  5. 5

    Diehl, V., Henle, G., Henle, W. & Kohn, G. J. Virol. 2, 663–669 (1968).

  6. 6

    Reedman, B. & Klein, G. Int. J. Cancer 11, 499–504 (1973).

  7. 7

    Epstein, M. & Achong, B. Lancet ii, 836–839 (1973).

  8. 8

    Rickinson, A., Jarvis, J., Crawford, D. & Epstein, M. Int. J. Cancer 14, 704–715 (1974).

  9. 9

    Miller, G. & Lipman, M. J. exp. Med. 138, 1398–1412 (1973).

  10. 10

    Klein, G., Svedmyr, E., Jondal, M. & Persson, P. Int. J. Cancer 17, 21–26 (1976).

  11. 11

    Katsuki, T. et al. Int. J. Cancer 23, 746–750 (1979).

  12. 12

    Hinuma, Y. & Katsuki, T. Int. J. Cancer. 21, 426–431 (1978).

  13. 13

    Robinson, J. et al. New Engl. J. Med. 302, 1293–1297 (1980).

  14. 14

    Niederman, J., McCollum, R., Henle, G. & Henle, W. J. Am. med. Ass. 203, 205–209 (1968).

  15. 15

    Svedmyr, E. & Jondal, M. Proc. natn. Acad. Sci. U.S.A. 72, 1622–1626 (1975).

  16. 16

    Böyum, A. Scand. J. clin. Lab. Invest. Suppl. 21, 77–89 (1968).

  17. 17

    Gershon, A., Kalter, Z. & Steinberg, S. Proc. Soc. exp. Biol. med. 151, 762–765 (1976).

Download references

Author information


  1. Departments of Pediatrics and Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut, 06510

    • James Robinson
    • , Douglas Smith
    •  & James Niederman


  1. Search for James Robinson in:

  2. Search for Douglas Smith in:

  3. Search for James Niederman in:

About this article

Publication history



Issue Date



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.